TIAA CREF Investment Management LLC reduced its position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 5.9% during the first quarter, Holdings Channel reports. The firm owned 24,110 shares of the specialty pharmaceutical company’s stock after selling 1,516 shares during the period. TIAA CREF Investment Management LLC’s holdings in Eagle Pharmaceuticals were worth $2,000,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA increased its position in Eagle Pharmaceuticals by 15.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,548 shares of the specialty pharmaceutical company’s stock worth $128,000 after buying an additional 202 shares during the period. Mason Street Advisors LLC increased its position in Eagle Pharmaceuticals by 10.2% in the first quarter. Mason Street Advisors LLC now owns 1,895 shares of the specialty pharmaceutical company’s stock worth $157,000 after buying an additional 175 shares during the period. Campbell Newman Asset Management Inc. acquired a new position in Eagle Pharmaceuticals during the first quarter worth $213,000. Louisiana State Employees Retirement System increased its position in Eagle Pharmaceuticals by 3.1% in the first quarter. Louisiana State Employees Retirement System now owns 3,300 shares of the specialty pharmaceutical company’s stock worth $274,000 after buying an additional 100 shares during the period. Finally, Thrivent Financial for Lutherans increased its position in Eagle Pharmaceuticals by 1.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $333,000 after buying an additional 60 shares during the period.

Eagle Pharmaceuticals, Inc. (EGRX) opened at 47.94 on Monday. Eagle Pharmaceuticals, Inc. has a 12 month low of $46.38 and a 12 month high of $97.15. The stock has a 50 day moving average of $73.55 and a 200-day moving average of $77.30. The company has a market cap of $733.39 million, a P/E ratio of 7.53 and a beta of 1.31.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.44 by $0.02. Eagle Pharmaceuticals had a return on equity of 79.25% and a net margin of 44.48%. The firm had revenue of $76.80 million during the quarter, compared to the consensus estimate of $70.10 million. During the same quarter in the previous year, the company earned ($0.06) EPS. The business’s revenue was up 159.5% compared to the same quarter last year. Equities research analysts expect that Eagle Pharmaceuticals, Inc. will post $3.38 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “TIAA CREF Investment Management LLC Has $2 Million Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/07/tiaa-cref-investment-management-llc-has-2-million-position-in-eagle-pharmaceuticals-inc-nasdaqegrx.html.

A number of research analysts recently weighed in on EGRX shares. BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Royal Bank Of Canada set a $86.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, April 24th. Piper Jaffray Companies set a $118.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, July 25th. ValuEngine downgraded shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Finally, Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 10th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $84.00.

In other news, CFO Pete A. Meyers bought 350 shares of Eagle Pharmaceuticals stock in a transaction dated Monday, June 12th. The stock was purchased at an average price of $71.49 per share, for a total transaction of $25,021.50. Following the purchase, the chief financial officer now directly owns 350 shares in the company, valued at approximately $25,021.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders bought 805 shares of company stock valued at $61,790. Company insiders own 19.50% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.